2012
DOI: 10.1016/j.dld.2011.09.015
|View full text |Cite
|
Sign up to set email alerts
|

The use of methotrexate for treatment of inflammatory bowel disease in clinical practice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

3
28
3
3

Year Published

2013
2013
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 53 publications
(37 citation statements)
references
References 25 publications
3
28
3
3
Order By: Relevance
“…The rate of use of MTX in the SIBDC was 13.1%, which is higher than previously published [8]. This rate was higher for CD (17.4%) than for UC (7.2%).…”
Section: Discussioncontrasting
confidence: 51%
See 2 more Smart Citations
“…The rate of use of MTX in the SIBDC was 13.1%, which is higher than previously published [8]. This rate was higher for CD (17.4%) than for UC (7.2%).…”
Section: Discussioncontrasting
confidence: 51%
“…Limited data on the effectiveness of MTX in clinical practice is available, as the use of the drug is limited. In a recent retrospective analysis, MTX had been administered only to 2.1% of patients, despite effectiveness rates, 64.1% in CD patients and 47.8% in ulcerative colitis (UC) patients [8, 9]. …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…This effect is used for treatment of various diseases. Methotrexate 45 has demonstrated effective antineoplastic activity and thus, it is used in the treatment of certain forms of cancer, psoriasis, rheumatoid arthritis, lupus, inflammatory bowel disease, and scleroderma (van den Hoogen, Boerbooms, and van de Putte 1989;Scully, Anderson, and Cannon 1991;Murad et al 1993;Van Dooren-Greebe et al 1994;Kuhn et al 2002;Martínková et al 2007;Saibeni et al 2012). Methotrexate is less toxic than other chemotherapeutic drugs.…”
mentioning
confidence: 99%
“…Methotrexate is less toxic than other chemotherapeutic drugs. Moreover, it is the only cytostatic, 50 which has an antagonist, tetrahydrofolate leucovorin, which can minimize its side effects, and therefore it can be administrated at high dosage by a particular schedule (van den Hoogen, Boerbooms, and van de Putte 1989; Martínková et al 2007;Devlin 2011;Saibeni et al 2012).…”
mentioning
confidence: 99%